328 Batf3 dendritic cells and 4–1BB/4–1BB ligand axis are required at the effector phase within the tumor microenvironment for anti-PD-L1 efficacy

• Thomas Gajewski,
• Brendan Horton,
• Ken Hatogai,
• Andrea Ziblat,
• Emily Higgs

Affiliations

Thomas Gajewski

Aff1 grid.170205.10000000419367822University of Chicago Chicago IL USA

Brendan Horton

Aff1 grid.170205.10000000419367822Committee on Cancer Biology University of Chicago Chicago IL USA

Ken Hatogai

Department of Pathology, University of Chicago, Chicago, Illinois, USA

Andrea Ziblat

1 Laboratorio de Fisiopatología de la Inmunidad Innata, Instituto de Biologia y Medicina Experimental, Buenos Aires, Argentina

Emily Higgs

University of Chicago, Chicago, IL, USA